Adaptive partial drug approval: A health policy proposal

Charles F. Manski

doi:10.2202/1553-3832.1449

Adaptive partial drug approval: A health policy proposal

Charles F. Manski

Economics

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Charles Manski of Northwestern argues that the drug approval process should be more continuous, so that patients can have access to beneficial drugs earlier and at the same time there are incentives for longer term studies than the current system produces, which could limit problems like those caused by Vioxx.

Original language	English (US)
Article number	A9
Journal	Economists' Voice
Volume	6
Issue number	4
DOIs	https://doi.org/10.2202/1553-3832.1449
State	Published - 2009

Keywords

Clinical trials
Diversification
Food and Drug Administration

ASJC Scopus subject areas

Business, Management and Accounting(all)
Economics, Econometrics and Finance(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2202/1553-3832.1449

Cite this

@article{90eccfa315904adb98e60bec15680541,

title = "Adaptive partial drug approval: A health policy proposal",

abstract = "Charles Manski of Northwestern argues that the drug approval process should be more continuous, so that patients can have access to beneficial drugs earlier and at the same time there are incentives for longer term studies than the current system produces, which could limit problems like those caused by Vioxx.",

keywords = "Clinical trials, Diversification, Food and Drug Administration",

author = "Manski, {Charles F.}",

year = "2009",

doi = "10.2202/1553-3832.1449",

language = "English (US)",

volume = "6",

journal = "Economists' Voice",

issn = "1553-3832",

publisher = "Berkeley Electronic Press",

number = "4",

}

TY - JOUR

T1 - Adaptive partial drug approval

T2 - A health policy proposal

AU - Manski, Charles F.

PY - 2009

Y1 - 2009

N2 - Charles Manski of Northwestern argues that the drug approval process should be more continuous, so that patients can have access to beneficial drugs earlier and at the same time there are incentives for longer term studies than the current system produces, which could limit problems like those caused by Vioxx.

AB - Charles Manski of Northwestern argues that the drug approval process should be more continuous, so that patients can have access to beneficial drugs earlier and at the same time there are incentives for longer term studies than the current system produces, which could limit problems like those caused by Vioxx.

KW - Clinical trials

KW - Diversification

KW - Food and Drug Administration

UR - http://www.scopus.com/inward/record.url?scp=64549160709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64549160709&partnerID=8YFLogxK

U2 - 10.2202/1553-3832.1449

DO - 10.2202/1553-3832.1449

M3 - Article

AN - SCOPUS:64549160709

VL - 6

JO - Economists' Voice

JF - Economists' Voice

SN - 1553-3832

IS - 4

M1 - A9

ER -

Adaptive partial drug approval: A health policy proposal

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this